search
Back to results

Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury (CITRIS-ALI)

Primary Purpose

Acute Lung Injury, Sepsis

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Ascorbic Acid
Placebo: 5% Dextrose in water
Sponsored by
Virginia Commonwealth University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acute Lung Injury

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients must have suspected or proven infection, and meet 2 out of 4 of the criteria for Systemic Inflammatory Response (SIRS) due to infection, and be accompanied by at least 1 criterion for sepsis-induced organ dysfunction, and meet all 5 criteria for Acute Respiratory Distress Syndrome (ARDS).
  • Suspected or proven infection: (e.g., thorax, urinary tract, abdomen, skin, sinuses, central venous catheters, and central nervous system, see Appendix A).
  • The presence of a systemic inflammatory response: Defined as: fever: >38ºC (any route) or hypothermia: <36ºC (core temp only), tachycardia: heart rate > 90 beats/min or receiving medications that slow heart rate or paced rhythm, leukocytosis: >12,000 WBC/µL or leukopenia: <4,000 WBC/µL or >10% band forms. Respiratory rate > 20 breaths per minute or PaCO2 < 32 or invasive mechanical ventilation.
  • The presence of sepsis associated organ dysfunction: (any of the following thought to be due to infection)
  • Sepsis associated hypotension (systolic blood pressure (SBP) < 90 mm Hg or an SBP decrease > 40 mm Hg unexplained by other causes or use of vasopressors for blood pressure support (epinephrine, norepinephrine, dopamine =/> 5mcg, phenylephrine, vasopressin)
  • Arterial hypoxemia (PaO2/FiO2 < 300) or supplemental O2 > 6LPM.
  • Lactate > upper limits of normal laboratory results
  • Urine output < 0.5 ml/kg/hour for > two hours despite adequate fluid resuscitation
  • Platelet count < 100,000 per mcL
  • Coagulopathy (INR > 1.5)
  • Bilirubin > 2 mg/dL
  • Glasgow Coma Scale < 11 or a positive CAM ICU score
  • ARDS characterized by all the following criteria
  • Lung injury of acute onset, within 1 week of an apparent clinical insult and with progression of respiratory symptoms
  • Bilateral opacities on chest imaging not explained by other pulmonary pathology (e.g. pleural effusions, lung collapse, or nodules)
  • Respiratory failure not explained by heart failure or volume overload
  • Decreased arterial PaO2/FiO2 ratio ≤ 300 mm Hg
  • Minimum PEEP of 5 cmH2O (may be delivered noninvasively with CPAP to diagnose mild ARDS

Exclusion Criteria:

  • Known allergy to Vitamin C
  • inability to obtain consent;
  • age < 18 years;
  • No indwelling venous or arterial catheter in patients requiring insulin in a manner that requires glucose being checked more than twice daily (e.g. continuous infusion, sliding scale);
  • presence of diabetic ketoacidosis;
  • more than 48 hrs since meeting ARDS criteria;
  • patient or surrogate or physician not committed to full support (not excluded if patient would receive all supportive care except for cardiac resuscitation);
  • pregnancy or breast feeding,
  • moribund patient not expected to survive 24 hours;
  • home mechanical ventilation (via tracheotomy or noninvasive) except for CPAP/BIPAP used only for sleep-disordered breathing;
  • home O2 > 2LPM, except for with CPAP/BIPAP
  • diffuse alveolar hemorrhage (vasculitis);
  • interstitial lung disease requiring continuous home oxygen therapy;
  • Active kidney stone
  • Non English speaking;
  • Ward of the state (inmate, other)

Sites / Locations

  • Emory University and Grady Memorial Hospital
  • University of Kentucky
  • The Cleveland Clinic
  • Virginia Commonwealth University Health System
  • Froedtert and The Medical College of Wisconsin

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Ascorbic Acid

5% Dextrose in Water

Arm Description

200mg/kg/day divided over 4 doses. Administered every 6 hours for 96 hours

50ml every 6 hours for 96 hours

Outcomes

Primary Outcome Measures

Modified Change in Sequential Organ Failure Assessment (mSOFA) Score
mSOFA is a single score based on patient status of five different biological systems: respiratory, cardiovascular, coagulation, renal, and neurological. Scores range from 0 to 20 with higher scores indicated worse status.
C-Reactive Protein at Study Hours 0, 48, 96, 168 When Compared to Placebo
Thrombomodulin Protein at Study Hours 0, 48, 96, 168 When Compared to Placebo

Secondary Outcome Measures

Oxygenation Index (FiO2 x Mean Airway Pressure/PaO2) at Study Hour 0, 48, 96, 168 if Still Intubated in Ascorbate Infused Patient Compared to Placebo.
VE-40 (Vent RR x TV/Weight) x (PaCO2/40) at Study Hour 0, 48, 96, 168 if Still Intubated, in Ascorbate Infused Patient Compared to Placebo
Estimate of Shunt
mSOFA Scores at Hours 0, 48, 96
mSOFA is a single score based on patient status of five different biological systems: respiratory, cardiovascular, coagulation, renal, and neurological. Scores range from 0 to 20 with higher scores indicated worse status.
Ascorbate Level at Hour 0, 48, 96, 168
Ventilator Free Days to Day 28
ICU-free Days at Day 28
All Cause Mortality to Day 28
Hospital-free Days at Day 60
Procalcitonin at Study Hour 0, 48, 96, 168
Receptor for Advanced Glycation Endpoints at Study Hour 0, 48, 96, 168
Tissue Factor Pathway Inhibitor at Study Hour 0, 48, 96, 168
Oxygenation Score: Pressure
Oxygenation as measure by the ratio of arterial oxygen partial pressure to fractional inspired oxygen (PaO2/FiO2). Scores range from 100 to 300 with lower values indicating more worse outcomes
Oxygenation Score: Saturation
Oxygenation as measure by the ratio of arterial oxygen saturation to fraction of inspired oxygen SpO2/FiO2
Coagulation
Coagulation as measured by Platelets per unit of blood. Scores range from less than 20 to more than 150. Lower scores indicate worse outcomes
Liver Function
Liver function as measured by Total Bilirubin. Normal levels range from 0.2 - 1.2. Levels greater than 1.2 indicate worse outcomes
Cardiovascular Function
Cardiovascular function as measured by Mean arterial pressure. Scores less than 70 mmHg indicate worse outcomes.
State of Consciousness
State of consciousness as measure by Glasgow Coma Scale which gives a score based on eye, verbal, and motor responses. Scores range from 3 to 15 with lower scores indicating worse outcome
Renal Function
Renal function as measured by Creatinine. Scores range from less than 1.2 to greater than 5.0 with higher scores indicating worse outcomes

Full Information

First Posted
March 27, 2014
Last Updated
October 14, 2019
Sponsor
Virginia Commonwealth University
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
search

1. Study Identification

Unique Protocol Identification Number
NCT02106975
Brief Title
Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury
Acronym
CITRIS-ALI
Official Title
Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury
Study Type
Interventional

2. Study Status

Record Verification Date
October 2019
Overall Recruitment Status
Completed
Study Start Date
April 2014 (undefined)
Primary Completion Date
November 16, 2017 (Actual)
Study Completion Date
January 8, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Virginia Commonwealth University
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Hypothesis 1A: Vitamin C infusion will significantly attenuate sepsis-induced systemic organ failure as measured by Sequential Organ Failure Assessment (SOFA) score, Hypothesis 1B: Vitamin C infusion will attenuate sepsis-induced lung injury as assessed by the oxygenation index and the VE40 Hypothesis 1C: Vitamin C infusion will attenuate biomarkers of inflammation (C-Reactive Protein, Procalcitonin), vascular injury (Thrombomodulin, Angiopoietin-2), alveolar epithelial injury (Receptor for Advanced Glycation Products), while inducing the onset of a fibrinolytic state (Tissue Factor Pathway Inhibitor).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Lung Injury, Sepsis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
170 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Ascorbic Acid
Arm Type
Active Comparator
Arm Description
200mg/kg/day divided over 4 doses. Administered every 6 hours for 96 hours
Arm Title
5% Dextrose in Water
Arm Type
Placebo Comparator
Arm Description
50ml every 6 hours for 96 hours
Intervention Type
Drug
Intervention Name(s)
Ascorbic Acid
Other Intervention Name(s)
Vitamin C
Intervention Description
Intervention
Intervention Type
Drug
Intervention Name(s)
Placebo: 5% Dextrose in water
Intervention Description
Placebo
Primary Outcome Measure Information:
Title
Modified Change in Sequential Organ Failure Assessment (mSOFA) Score
Description
mSOFA is a single score based on patient status of five different biological systems: respiratory, cardiovascular, coagulation, renal, and neurological. Scores range from 0 to 20 with higher scores indicated worse status.
Time Frame
96 hours
Title
C-Reactive Protein at Study Hours 0, 48, 96, 168 When Compared to Placebo
Time Frame
up to 168 hours
Title
Thrombomodulin Protein at Study Hours 0, 48, 96, 168 When Compared to Placebo
Time Frame
Up to 168 hours
Secondary Outcome Measure Information:
Title
Oxygenation Index (FiO2 x Mean Airway Pressure/PaO2) at Study Hour 0, 48, 96, 168 if Still Intubated in Ascorbate Infused Patient Compared to Placebo.
Time Frame
Up to hour 168
Title
VE-40 (Vent RR x TV/Weight) x (PaCO2/40) at Study Hour 0, 48, 96, 168 if Still Intubated, in Ascorbate Infused Patient Compared to Placebo
Description
Estimate of Shunt
Time Frame
Up to hour 168
Title
mSOFA Scores at Hours 0, 48, 96
Description
mSOFA is a single score based on patient status of five different biological systems: respiratory, cardiovascular, coagulation, renal, and neurological. Scores range from 0 to 20 with higher scores indicated worse status.
Time Frame
Up to hour 96
Title
Ascorbate Level at Hour 0, 48, 96, 168
Time Frame
Up to hour 168
Title
Ventilator Free Days to Day 28
Time Frame
Up to Day 28
Title
ICU-free Days at Day 28
Time Frame
Up to Day 28
Title
All Cause Mortality to Day 28
Time Frame
Up to Day 28
Title
Hospital-free Days at Day 60
Time Frame
Up to Day 60
Title
Procalcitonin at Study Hour 0, 48, 96, 168
Time Frame
Up to hour 168
Title
Receptor for Advanced Glycation Endpoints at Study Hour 0, 48, 96, 168
Time Frame
Up to hour 168
Title
Tissue Factor Pathway Inhibitor at Study Hour 0, 48, 96, 168
Time Frame
Up to hour 168
Title
Oxygenation Score: Pressure
Description
Oxygenation as measure by the ratio of arterial oxygen partial pressure to fractional inspired oxygen (PaO2/FiO2). Scores range from 100 to 300 with lower values indicating more worse outcomes
Time Frame
Up to hour 168
Title
Oxygenation Score: Saturation
Description
Oxygenation as measure by the ratio of arterial oxygen saturation to fraction of inspired oxygen SpO2/FiO2
Time Frame
Up to hour 168
Title
Coagulation
Description
Coagulation as measured by Platelets per unit of blood. Scores range from less than 20 to more than 150. Lower scores indicate worse outcomes
Time Frame
Up to hour 168
Title
Liver Function
Description
Liver function as measured by Total Bilirubin. Normal levels range from 0.2 - 1.2. Levels greater than 1.2 indicate worse outcomes
Time Frame
Up to hour 168
Title
Cardiovascular Function
Description
Cardiovascular function as measured by Mean arterial pressure. Scores less than 70 mmHg indicate worse outcomes.
Time Frame
Up to hour 168
Title
State of Consciousness
Description
State of consciousness as measure by Glasgow Coma Scale which gives a score based on eye, verbal, and motor responses. Scores range from 3 to 15 with lower scores indicating worse outcome
Time Frame
Up to hour 168
Title
Renal Function
Description
Renal function as measured by Creatinine. Scores range from less than 1.2 to greater than 5.0 with higher scores indicating worse outcomes
Time Frame
Up to hour 168

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients must have suspected or proven infection, and meet 2 out of 4 of the criteria for Systemic Inflammatory Response (SIRS) due to infection, and be accompanied by at least 1 criterion for sepsis-induced organ dysfunction, and meet all 5 criteria for Acute Respiratory Distress Syndrome (ARDS). Suspected or proven infection: (e.g., thorax, urinary tract, abdomen, skin, sinuses, central venous catheters, and central nervous system, see Appendix A). The presence of a systemic inflammatory response: Defined as: fever: >38ºC (any route) or hypothermia: <36ºC (core temp only), tachycardia: heart rate > 90 beats/min or receiving medications that slow heart rate or paced rhythm, leukocytosis: >12,000 WBC/µL or leukopenia: <4,000 WBC/µL or >10% band forms. Respiratory rate > 20 breaths per minute or PaCO2 < 32 or invasive mechanical ventilation. The presence of sepsis associated organ dysfunction: (any of the following thought to be due to infection) Sepsis associated hypotension (systolic blood pressure (SBP) < 90 mm Hg or an SBP decrease > 40 mm Hg unexplained by other causes or use of vasopressors for blood pressure support (epinephrine, norepinephrine, dopamine =/> 5mcg, phenylephrine, vasopressin) Arterial hypoxemia (PaO2/FiO2 < 300) or supplemental O2 > 6LPM. Lactate > upper limits of normal laboratory results Urine output < 0.5 ml/kg/hour for > two hours despite adequate fluid resuscitation Platelet count < 100,000 per mcL Coagulopathy (INR > 1.5) Bilirubin > 2 mg/dL Glasgow Coma Scale < 11 or a positive CAM ICU score ARDS characterized by all the following criteria Lung injury of acute onset, within 1 week of an apparent clinical insult and with progression of respiratory symptoms Bilateral opacities on chest imaging not explained by other pulmonary pathology (e.g. pleural effusions, lung collapse, or nodules) Respiratory failure not explained by heart failure or volume overload Decreased arterial PaO2/FiO2 ratio ≤ 300 mm Hg Minimum PEEP of 5 cmH2O (may be delivered noninvasively with CPAP to diagnose mild ARDS Exclusion Criteria: Known allergy to Vitamin C inability to obtain consent; age < 18 years; No indwelling venous or arterial catheter in patients requiring insulin in a manner that requires glucose being checked more than twice daily (e.g. continuous infusion, sliding scale); presence of diabetic ketoacidosis; more than 48 hrs since meeting ARDS criteria; patient or surrogate or physician not committed to full support (not excluded if patient would receive all supportive care except for cardiac resuscitation); pregnancy or breast feeding, moribund patient not expected to survive 24 hours; home mechanical ventilation (via tracheotomy or noninvasive) except for CPAP/BIPAP used only for sleep-disordered breathing; home O2 > 2LPM, except for with CPAP/BIPAP diffuse alveolar hemorrhage (vasculitis); interstitial lung disease requiring continuous home oxygen therapy; Active kidney stone Non English speaking; Ward of the state (inmate, other)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alpha B. Fowler, MD
Organizational Affiliation
Virginia Commonwealth University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Emory University and Grady Memorial Hospital
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30322
Country
United States
Facility Name
University of Kentucky
City
Lexington
State/Province
Kentucky
ZIP/Postal Code
40506
Country
United States
Facility Name
The Cleveland Clinic
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44106
Country
United States
Facility Name
Virginia Commonwealth University Health System
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23298
Country
United States
Facility Name
Froedtert and The Medical College of Wisconsin
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53226
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
31573637
Citation
Fowler AA 3rd, Truwit JD, Hite RD, Morris PE, DeWilde C, Priday A, Fisher B, Thacker LR 2nd, Natarajan R, Brophy DF, Sculthorpe R, Nanchal R, Syed A, Sturgill J, Martin GS, Sevransky J, Kashiouris M, Hamman S, Egan KF, Hastings A, Spencer W, Tench S, Mehkri O, Bindas J, Duggal A, Graf J, Zellner S, Yanny L, McPolin C, Hollrith T, Kramer D, Ojielo C, Damm T, Cassity E, Wieliczko A, Halquist M. Effect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients With Sepsis and Severe Acute Respiratory Failure: The CITRIS-ALI Randomized Clinical Trial. JAMA. 2019 Oct 1;322(13):1261-1270. doi: 10.1001/jama.2019.11825. Erratum In: JAMA. 2020 Jan 28;323(4):379.
Results Reference
derived

Learn more about this trial

Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury

We'll reach out to this number within 24 hrs